Abstract:Objectives: Non-alcoholic steatohepatitis (NASH) is the second most common cause of the hepatitis. In this study, we aimed to investigate the effects and mechanisms of Cyclocarya paliurus (CPF) flavonoids extract in the treatment of NASH. To achieve this, we performed compound target prediction and network analysis based on the method of network pharmacology. We investigated the effect of CPF extract on NASH and the underlying molecular mechanisms using the in vivo pharmacological evaluation technique. Materials and Methods: First, NASH was induced in mice with a high-fat diet. Furthermore, experimental validation was carried out with a high-fat feed-induced NASH mouse model. Chemical compounds and human target proteins of CPF, as well as NASH-related human genes, were obtained from TCMSP, PubChem, and GenBank Database, respectively. Subsequently, molecular networks and typical pathways presumably involved in the treatment of CPF on NASH were performed by Metoscape and String software. Then, the network was constructed by using Cytoscape v3.7.2. The Kyoto Encyclopedia of Genes and Genomes pathway enrichment was performed by using Database for Annotation. Then, the possible underlying mechanisms were studied using the quantitative reverse transcription polymerase chain reaction and Western blot analysis. Results: The network pharmacology research showed that the CPF, which contained 26 compounds and 27 genes, regulated the most signaling pathways related to NASH. Moreover, the protein–protein interaction network based on the targets of CPF on NASH revealed that the core compounds were luteolin, quercetin, kaempferol, ellagic acid, isoquercitrin, gallic acid, inositol, and myricetin, which were regulated by more than 4 compounds, remarkable related with peroxisome proliferator-activated receptor (PPAR) signaling pathway, cholesterol metabolism, bile secretion, type II diabetes mellitus, adenosine 5′-monophosphate-activated protein kinase signaling pathway, and insulin signaling pathway. In addition, carnitine palmitoyltransferase 2, cytochrome P450 family 7 subfamily A member 1 (CYP7A1), cytochrome P450 family 27 subfamily A member 1 (CYP27A1), and fatty acid-binding protein 1 were treated as target genes of CPF in NASH. In vivo experiments indicated that CPF promoted Peroxisome proliferator-activated receptor alpha (PPAR α)/Peroxisome proliferator-activated receptor gamma (PPAR γ) signaling pathway in NASH mouse model. Conclusion: CPF played a role in inhibiting lipid response in NASH, which was closely associated with the modulation effect of CPF on PPAR α/PPAR γ signaling pathway.

Meta‐analysis: analysis of mechanistic pathways in the treatment of non‐alcoholic steatohepatitis. Evidence from a Bayesian network meta‐analysis

Effects of Bariatric Endoscopy on Non-Alcoholic Fatty Liver Disease: A Comprehensive Systematic Review and Meta-Analysis

A Class Effect Network Meta-analysis of Lipid Modulation in Non-alcoholic Steatohepatitis for Dyslipidemia

Drug targets regulate systemic metabolism and provide new horizons to treat nonalcoholic steatohepatitis

A novel bioinformatics strategy to uncover the active ingredients and molecular mechanisms of Bai Shao in the treatment of non-alcoholic fatty liver disease

Effects of cyclocarya paliurus flavonoid extract in non-alcoholic steatohepatitis mice: Intermeshing network pharmacology and in vivo pharmacological evaluation

Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives

Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets

Integrated Multichip Analysis Identifies Potential Key Genes in the Pathogenesis of Nonalcoholic Steatohepatitis

The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment: A PRISMA-compliant network meta-analysis of randomized controlled trials

Efficacy and Safety of Treatments for Patients with Portal Hypertension and Cirrhosis: A Systematic Review and Bayesian Network Meta-Analysis

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)

Integrated Pharmaco-Bioinformatics Approaches and Experimental Verification To Explore the Effect of Britanin on Nonalcoholic Fatty Liver Disease

Network Pharmacology Analysis and Experimental Validation to Explore the Anti-inflammatory Mechanism of Asiatic Acid on Alcoholic Steatohepatitis

Integrated network pharmacology, metabolomics, and transcriptomics of Huanglian-Hongqu herb pair in non-alcoholic fatty liver disease

Use of probiotics, prebiotics, and synbiotics in non‐alcoholic fatty liver disease: A systematic review and meta‐analysis

Integrated transcriptomic landscape of the effect of anti‐steatotic treatments in high‐fat diet mouse models of non‐alcoholic fatty liver disease

Exploration of potential targets and mechanisms of naringenin in the treatment of nonalcoholic fatty liver disease through network pharmacology

The Role of the Intestinal Microbiota in Nonalcoholic Steatohepatitis

Methodological Concerns about a Recent Meta‐analysis of the Influence of the I148M Variant of Patatin‐like Phospholipase Domain Containing 3 on the Susceptibility and Histological Severity of Nonalcoholic Fatty Liver Disease

A consortium of Hordeum vulgare and gut microbiota against non-alcoholic fatty liver disease via data-driven analysis